ReviewCancers2019
Immune Therapy for Liver Cancers.
Review in Cancers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- Regulated necrosis at the crossroads of liver inflammation and cancer development.Nature reviews. Gastroenterology & hepatology · 2026Review
- Modeling the response to interleukin-21 to inform natural killer cell immunotherapy.Immunology and cell biology · 2025Article
- Advanced Technologies for Cancer Immunotherapy: Focus on Gastrointestinal Cancers.Anti-cancer agents in medicinal chemistry · 2025Review
- SPATS2 is correlated with cell cycle progression and immune cells infiltration in hepatocellular carcinoma.BMC gastroenterology · 2023Article
- Article
- Pan-Cancer Landscape of NEIL3 in Tumor Microenvironment: A Promising Predictor for Chemotherapy and Immunotherapy.Cancers · 2022Article
- Downregulation of TUSC3 promotes EMT and hepatocellular carcinoma progression through LIPC/AKT axis.Journal of translational medicine · 2022Article
- Targeted regulation of tumor microenvironment through the inhibition of MDSCs by curcumin loaded self-assembled nano-filaments.Materials today. Bio · 2022Article
- Mechanism of HBV-positive liver cancer cell exosomal miR-142-3p by inducing ferroptosis of M1 macrophages to promote liver cancer progression.Translational cancer research · 2022Article
- Drug delivery strategy in hepatocellular carcinoma therapy.Cell communication and signaling : CCS · 2022Review
- New insights into a microvascular invasion prediction model in hepatocellular carcinoma: A retrospective study from the SEER database and China.Frontiers in surgery · 2022Article
- Establishment of a lncRNA-Based Prognostic Gene Signature Associated With Altered Immune Responses in HCC.Frontiers in immunology · 2022Article
- Investigations of nitazoxanide molecular targets and pathways for the treatment of hepatocellular carcinoma using network pharmacology and molecular docking.Frontiers in pharmacology · 2022Article
- Construction and experimental verification of user-friendly molecular subtypes mediated by immune-associated genes in hepatocellular carcinoma.Frontiers in oncology · 2022Article
- IncreasedJournal of gastrointestinal oncology · 2021Article
- Immunodiagnostic Biomarkers for Hepatocellular Carcinoma (HCC): The First Step in Detection and Treatment.International journal of molecular sciences · 2021Review
- Single-cell Long Non-coding RNA Landscape of T Cells in Human Cancer Immunity.Genomics, proteomics & bioinformatics · 2021Article
- Low expression of AQP9 and its value in hepatocellular carcinoma.Translational cancer research · 2021Article
- Fibrinogen-like protein 2 promotes the accumulation of myeloid-derived suppressor cells in the hepatocellular carcinoma tumor microenvironment.Oncology letters · 2021Article
- SSRP1 Is a Prognostic Biomarker Correlated with CD8BioMed research international · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Hepatocellular carcinoma (HCC) and biliary tract cancers (BTC) display a poor prognosis with 5-year overall survival rates around 15%, all stages taken together. These primary liver malignancies are often diagnosed at advanced stages where therapeutic options are limited. Recently, immune therapy has opened new opportunities in oncology. Based on their high programmed death-ligand 1 expression and tumor-infiltrating lymphocytes, HCC and BTC are theoretically good candidates for immune checkpoint blockade. However, clinical activity of single agent immunotherapy appears limited to a subset of patients, which is still ill-defined, and combinations are under investigation. In this review, we provide an overview of (i) the biological rationale for immunotherapies in HCC and BTC, (ii) the current state of their clinical development, and (iii) the predictive value of immune signatures for both clinical outcome and response to these therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.